ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aurinia reports favourable assessment of LUPKYNIS in ICER
March 18, 2021Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis. -
Catalent, Aurinia Ink LUPKYNIS Commercial Supply Pact
February 20, 2021Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN). -
Aurinia and Lonza Expand Manufacturing Partnership
December 17, 2020Aurinia Pharmaceuticals and Lonza have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp ... -
Aurinia begins voclosporin trial in kidney transplant recipients with Covid-19
October 30, 2020Aurinia Pharmaceuticals has announced the commencement of an open-label exploratory trial to assess antiviral activity of voclosporin in kidney transplant recipients (KTRs) with Covid-19. -
Aurinia Pharmaceuticals: Where to From Here?
April 01, 2017March has proven to be a rollercoaster ride for shareholders of Aurinia Pharmaceuticals (NASDAQ:AUPH), with shares climbing almost 200% at one point before pulling back.
Pharma Sources Insight January 2025
